Exact label fit
The MASH indication is specific to diagnosis, fibrosis stage, age, and route
The current Novo Nordisk prescribing information identifies a narrow MASH treatment population: adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2 to F3. The label places this indication under Wegovy injection and pairs treatment with reduced-calorie diet and increased physical activity. Wegovy tablets have labeled adult weight-management and cardiovascular-risk contexts, but the current tablet indication does not include MASH. A patient should not infer eligibility from obesity, type 2 diabetes, a fatty-liver ultrasound, an elevated liver enzyme, or a semaglutide prescription alone.
- Confirm the written diagnosis, fibrosis assessment, whether cirrhosis is present, the prescribing specialist’s rationale, and the exact Wegovy injection prescription.
- Do not call all MASLD or “fatty liver” MASH; MASH includes liver inflammation and injury, and the labeled fibrosis boundary matters.
- Do not transfer the MASH indication to Wegovy tablets, Ozempic injection or tablets, Rybelsus, a patient-specific compound, or a no-prescription semaglutide product.
Diagnosis and staging
A scan or liver-enzyme result does not establish the labeled MASH population by itself
NIDDK explains that clinicians use medical history, physical examination, blood tests, imaging, and sometimes liver biopsy to evaluate fatty-liver disease and distinguish forms of liver injury. Routine imaging can show liver fat, but NIDDK notes that it cannot by itself show inflammation or fibrosis. Blood-based scores and specialized imaging may help assess advanced fibrosis, while the treating liver team decides whether additional testing is needed. Peptide12 cannot diagnose MASH or assign a fibrosis stage from an intake form.
- Bring prior liver-enzyme results, fibrosis scores, elastography or other imaging, biopsy reports when available, alcohol history, viral-hepatitis testing, medicine and supplement lists, and specialist notes.
- Ask which evidence supports MASH rather than isolated steatosis, which evidence supports F2 or F3 fibrosis, and how cirrhosis and other causes of liver disease were evaluated.
- Do not alter alcohol, symptom, medicine, weight, diabetes, or test history to fit a coverage or treatment criterion.
Accelerated approval
Biopsy improvements supported approval, but long-term clinical benefit still requires confirmation
The Wegovy label describes a randomized trial in adults with noncirrhotic MASH and biopsy-confirmed F2 or F3 fibrosis. At Week 72, the label reports resolution of steatohepatitis without worsening fibrosis in 63% of the Wegovy injection group and 34% of the placebo group; at least one-stage fibrosis improvement without worsening steatohepatitis occurred in 37% and 22%, respectively. These are study-population histopathology endpoints, not a promise that every patient will improve or avoid cirrhosis, liver failure, transplant, cancer, or death. The label explicitly uses accelerated-approval language and says continued approval may be contingent on confirmatory clinical benefit.
- Keep the Week 72 percentages tied to the label’s adult F2–F3 biopsy population, comparator, endpoints, and Wegovy injection—not to tablets or compounded semaglutide.
- Do not use weight-loss results, testimonials, liver-enzyme changes, or a before-and-after scan as a substitute for the labeled MASH evidence.
- Ask how the liver team will judge response, worsening, intolerance, and whether the treatment plan should change as confirmatory evidence and labeling evolve.
Safety and coordination
MASH care does not remove Wegovy’s product-specific warnings or interaction questions
The current Wegovy label carries a boxed warning about thyroid C-cell tumors observed in rodents and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. It also includes warnings and precautions involving pancreatitis, gallbladder disease, hypoglycemia with certain diabetes medicines, acute kidney injury due to volume depletion, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation. The relevance of each issue depends on the individual and exact presentation.
- Reconcile insulin, sulfonylureas and other diabetes medicines, blood-pressure medicines, diuretics, oral medicines, supplements, alcohol use, and any other semaglutide or GLP-1 product.
- Discuss severe gastrointestinal disease, persistent vomiting or diarrhea, dehydration, kidney problems, gallstones, pancreatitis history, vision changes, thyroid history, mood symptoms, pregnancy plans, breastfeeding, and upcoming procedures.
- Do not combine GLP-1 products, copy an online titration schedule, restart after a gap, or change another medicine without the prescribing clinicians’ coordination.
Monitoring and escalation
The plan should cover liver follow-up, cardiometabolic care, tolerability, and urgent symptoms
MASH commonly overlaps with obesity, type 2 diabetes, high blood pressure, abnormal lipids, cardiovascular risk, and other liver conditions. The label trial used Wegovy alongside standard care for cardiometabolic conditions and lifestyle counseling. A treatment plan should therefore define who manages liver follow-up, glucose and blood-pressure medicines, nutrition, adverse effects, procedures, refill decisions, and access problems. Normal-feeling days or weight change alone do not show whether fibrosis or other liver risks are improving.
- Ask what baseline and follow-up liver, metabolic, kidney, glucose, eye, nutrition, or other assessments are appropriate and which clinician receives the results.
- Seek urgent medical assessment for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, yellowing of the skin or eyes, vomiting blood, black stools, marked abdominal swelling, breathing trouble, or another dangerous-feeling change.
- Do not wait for a routine telehealth message when symptoms could represent serious dehydration, pancreatitis, gallbladder disease, bleeding, liver decompensation, allergy, or another emergency.
Branded, compounded, and access paths
A compounded semaglutide prescription is not FDA-approved Wegovy for MASH
Wegovy is a branded FDA-approved finished drug with formulation-specific labeling. A patient-specific compounded semaglutide preparation is not Wegovy, is not an FDA-approved finished drug, and does not inherit Wegovy’s MASH indication or trial results. Peptide12 lists clinician-reviewed Wegovy and compounded semaglutide injection pathways, but eligibility, a prescription, branded availability, insurance approval, pharmacy dispensing, and clinical response are never guaranteed. MASH treatment may also require specialist care and testing that routine telehealth cannot provide by itself.
- Verify branded Wegovy injection, the prescriber, dispensing pharmacy, patient label, coverage decision, complete cost, follow-up responsibilities, and specialist coordination before payment.
- Reject “generic Wegovy for fatty liver,” guaranteed fibrosis reversal, no-test approval, research-use semaglutide, hidden pharmacy identity, copied dose charts, or claims that compounding makes a product FDA approved.
- If coverage is denied or the product is unavailable, obtain the written reason and ask the liver and prescribing teams about evidence-based alternatives rather than borrowing, stockpiling, switching, or buying from an unverified seller.